

ASX ANNOUNCEMENT

28 March 2017

## Share Purchase Plan Scale-Back Refund

The Directors of Capitol Health Limited (ASX: CAJ, "Capitol" or the "Company") are pleased to report that refunds on the scale-back of the Company's oversubscribed Share Purchase Plan ("SPP") will be processed on or before Tuesday 4<sup>th</sup> April 2017.

Accordingly applicants who applied for an allotment of shares in excess of \$6,000 will have their excess funds returned by cheque or direct credit, in accordance with the payment instructions on record with the Company's share registry, Computershare.

Shares allocated under the SPP will be allotted on 11 April 2017 and commence trading on 12 April, subject to approval of the Private Placement at the Company's Extraordinary General Meeting on 5 April 2017.

Details regarding the oversubscribed SPP, the increase in the SPP amount and the scale back arrangements were previously released to market on 22 March 2017.

Once again, the Directors wish to thank all shareholders for their show of support for the Company and its transformation strategy.

---

**For more information, please contact:**

**Andrew Harrison**

Managing Director

Capitol Health Limited

Tel: (03) 9348 3333

[investors@capitolhealth.com.au](mailto:investors@capitolhealth.com.au)

### About Capitol Health

Capitol Health is a leading provider of diagnostic imaging and related services to the Australian healthcare market. Headquartered in Melbourne, Victoria, the Company owns and operates clinics throughout Victoria and New South Wales. The Company's operational focus is on delivering a community-based infrastructure for radiologists and related medical practitioners to deliver optimal, efficient, accurate healthcare service outcomes for patients.

Capitol also has an investment in diagnostic imaging artificial intelligence through Enlitic Inc in the US and a collaboration agreement with Enlitic regarding revenue share from the sale of Enlitic's Deep Learning Services in the radiology field in China.

Capitol also recently entered the Chinese DI market with a Joint Venture with CITIC Pharmaceutical (Shenzhen) Co., Ltd ("CITIC Pharmaceutical") and Xiamen Zhouxin Medical Image Co., Ltd (Zhouxin) to provide consulting and clinic management services to a network of independent imaging clinics to be created by CITIC and Zhouxin across mainland China.